Pfizer Limited shareholders have overwhelmingly approved a final dividend of ₹75 per equity share for FY26 and reappointed P. Rengan as a director during its 75th Annual General Meeting (AGM). The virtual meeting, held on July 28, 2026, saw all four resolutions pass with more than 99% support from voting members, underscoring strong stakeholder confidence in the company’s governance and financial distribution plans.

The e-voting results were filed with the BSE and NSE pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting was conducted via Video Conferencing and Other Audio-Visual Means (VC/OVAM) in compliance with Ministry of Corporate Affairs (MCA) and SEBI circulars. Pradip Shah, Chairman and Non-Independent Non-Executive Director, chaired the session from Mumbai, while Ms. Meenakshi Nevatia, Managing Director, presented the company’s performance overview.

Voting Results Breakdown

A total of 391 members cast votes across remote e-voting and live electronic polling, representing approximately 81.96% of the outstanding shares. The promoter group, holding 63.92% of the capital, voted in favor of all resolutions without any dissent. Public institutional investors also showed near-unanimous support, while retail participation remained low but largely positive.

The dividend declaration represents a significant return to shareholders for the financial year ended March 31, 2026. The re-appointment of Mr. P. Rengan (DIN: 10362899), who retired by rotation under Section 152(6) of the Companies Act, 2013, ensures continuity in board oversight of plant operations. Additionally, shareholders ratified the remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants, for the financial year ending March 31, 2027.

Governance and Compliance

CS Nrupang B. Dholakia, Managing Partner of Dholakia & Associates LLP, served as the independent scrutinizer for the voting process. The remote e-voting window ran from July 24 to July 27, 2026, followed by a 15-minute live e-voting period during the AGM. Statutory Auditors, Secretarial Auditor, and Cost Auditor attended via video conference; their reports contained no qualifications or adverse remarks. Physical copies of the Annual Report were dispatched only upon request, aligning with digital-first communication policies.

Pfizer reported a year-on-year increase in net profit for the quarter ended June 30, 2026 (Q1FY27), rising 6.6% to ₹204.47 crore from ₹191.75 crore in the corresponding period last year. The pharmaceutical company’s revenue from operations grew 8.3% to ₹653.17 crore, supported by an expansion in EBITDA margin to 37.9% from 34.83%. The results reflect improved operational leverage and cost management during the quarter.

The Board of Directors approved the unaudited financial results at a meeting held on July 28, 2026. The figures were reviewed by the Audit Committee and subsequently limited-reviewed by the statutory auditors, B S R & Co. LLP, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates in a single segment, Pharmaceuticals, and has no subsidiaries or joint ventures as of June 30, 2026.

Revenue and Profitability Performance

Pfizer’s revenue from operations stood at ₹653.17 crore in Q1FY27, compared to ₹603.05 crore in Q1FY26. Other income declined to ₹44.84 crore from ₹67.17 crore in the prior year period, resulting in total income of ₹698.01 crore against ₹670.22 crore previously.

EBITDA for the quarter was ₹246.15 crore (derived from profit before tax and exceptional items plus depreciation and finance costs), up from ₹210.14 crore in Q1FY26. The EBITDA margin expanded significantly to 37.9% from 34.83%, indicating stronger operating efficiency despite higher material costs.

Net Profit and Taxation

Net profit for the quarter increased to ₹204.47 crore from ₹191.75 crore in Q1FY26. Profit before tax rose to ₹276.68 crore from ₹259.53 crore. Tax expense for the quarter was ₹72.21 crore (current tax ₹70.93 crore and deferred tax ₹1.28 crore), compared to ₹67.78 crore in the previous year.

Earnings per share (basic and diluted) grew 6.6% to ₹44.69 per share from ₹41.91 per share in Q1FY26. The company’s paid-up equity share capital remained unchanged at ₹45.75 crore.

What the Numbers Show

The divergence between revenue growth (8.3%) and net profit growth (6.6%) suggests that while top-line momentum is strong, cost pressures partially offset margin gains. However, the significant expansion in EBITDA margin (+307 basis points) indicates that operational efficiencies—likely in employee benefits and other expenses—are driving profitability more than volume growth alone. The decline in other income (from ₹67.17 crore to ₹44.84 crore) highlights that core operational performance is now the primary driver of earnings, reducing reliance on non-operating income streams.